Humans share many of the same genes as dogs. In 2022, Anderson Cooper reported on how scientists were using that similarity in a field called comparative oncology, testing new cancer treatments on dogs and humans. "60 Minutes" is the most successful television broadcast in history. Offering hard-hitting investigative reports, interviews, feature segments and profiles of people in the news, the broadcast began in 1968 and is still a hit, over 50 seasons later, regularly making Nielsen's Top 10. Subscribe to ...

The complexity of cancer, with its bewildering variety of forms, makes devising treatments difficult. But progress is being made https://t.co/4IvNxwLPex ...

Group 1: Clinical Trial Results - Relay Therapeutics' zovegalisib demonstrated a median progression-free survival (PFS) of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer [1] - Median PFS was 11.2 months in patients with kinase mutations and 11.0 months in patients with non-kinase mutations [1][2] Group 2: Safety Profile - The safety profile of the 400mg BID fed regimen was consistent with previous findings from the 600mg BID fasted dose, reinforcing the drug's potential as a treatment option [2] Group 3: Stock Performance - Relay Therapeutics shares increased by 195.16% over the past 12 months, currently trading 8.6% above its 20-day simple moving average (SMA) and 30.3% above its 100-day SMA [3] - The RSI is at 60.72, indicating neutral territory, while the MACD is at 0.5310, suggesting bullish momentum [3][4] Group 4: Analyst Consensus - The stock carries a Buy Rating with an average price target of $17.20, with recent analyst actions including Guggenheim raising the target to $22.00 and Wells Fargo raising it to $15.00 [5][6] - Benzinga Edge scorecard indicates strong momentum, with a bullish score of 98.01, showing that the stock is outperforming the broader market [5] Group 5: Price Action and Support/Resistance Levels - Relay Therapeutics shares were down 1.45% at $10.21 at the time of publication, with key resistance at $11.50 and key support at $9.00 [6]

जल्दी-जल्दी चलेंगे थोड़ा सा स्लाइड दिखाऊंगा और कुछ जीवन के एक्सपीरियंस आपके साथ शेयर करता हूं। दिस इज द हॉस्पिटल व्हिच इज़ स्प्रेड ऑन 100 एक्सर्स ऑफ लैंड इन स्मॉल टाउन व्हिच वाज़ अबाउट 25,000 व्हेन आई गॉन देयर इन इन सतना मध्य प्रदेश। नेक्स्ट स्लाइड प्लीज। दिस इज अ कैंसर यूनिट स्टेट ऑफ आर्ट वि वास क्रिएटेड लेटर ऑन। नेक्स्ट स्लाइड प्लीज। नाउ एक लंबी जर्नी है चार दशक की। अ उसमें कुछ इमोशन भी है, कुछ ड्रामा भी है, एक्शन भी है। पूरी तरह से अच्छी पिक्चर आपको नजर आएगी। नेक्स्ट स्लाइड प्लीज। नाउ हाउ डू वी दिस वास अ ट ...

Market Overview - U.S. equity markets reached new all-time highs in Q4 2025, with the S&P 500 Index rising 2.66% and the Bloomberg U.S. Aggregate Bond Index increasing by 1.10% [1] - The U.S. economy showed resilience, although consumer confidence deteriorated toward year-end, raising concerns about future spending and the labor market [1] Fund Performance - The Aristotle Growth Equity Fund (Class I-2) returned 0.95%, underperforming the Russell 1000 Growth Index's 1.12% [1] - Poor security selection in the information technology and consumer discretionary sectors detracted from performance, while positive contributions from healthcare and industrials improved relative performance [1] Company Highlight: Revolution Medicines, Inc. - Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company focused on developing therapies for RAS-addicted cancers [2][3] - As of February 25, 2026, Revolution Medicines, Inc. stock closed at $103.24 per share, with a one-month return of 5.13% and a 52-week gain of 164.18% [2] - The company has a market capitalization of $19.958 billion [2] - Revolution Medicines is developing RAS(ON) inhibitors to block growth signals from RAS proteins, with main drugs including Daraxonrasib, Elironrasib, and Zoldonrasib already in clinical trials [3] - The company is also working on bringing a new drug, RMC-5127, into trials soon and developing targeted treatments for other types of RAS mutations [3]

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has appointed Sidney Braun as the CEO of its subsidiary Liora Technologies Europe Ltd., aiming to advance cancer treatment technologies, particularly the LiGHT System for proton therapy [1][4]. Company Overview - LIXTE is a clinical-stage pharmaceutical and med-tech company focused on developing and commercializing cancer therapies, with its lead compound LB-100 showing promise in enhancing chemotherapy and immunotherapy outcomes [5]. - The company is pioneering a new treatment paradigm in cancer biology known as activation lethality, supported by a comprehensive patent portfolio [5]. Leadership Appointment - Sidney Braun brings over 20 years of operational and strategic experience in the healthcare industry, having played a significant role in the creation of Liora and the acquisition of its assets by LIXTE [2][3]. - Braun's commitment to advancing the radiotherapy segment aims to achieve positive patient outcomes and long-term shareholder value for LIXTE [4]. Technology Focus - Liora is developing electronically controlled proton therapy systems, with the LiGHT System believed to offer significant advantages over existing technologies for tumor treatment [6].

Core Insights - Exelixis, Inc. (EXEL) reported better-than-expected fourth-quarter results for 2025, with adjusted earnings per share (EPS) of 94 cents, surpassing the Zacks Consensus Estimate of 77 cents and up from 55 cents in the same quarter last year [1][2][6] - The company achieved net revenues of $598.7 million, exceeding the Zacks Consensus Estimate of $585 million, representing a year-over-year increase of 5.6% [2][4] - Despite the positive results, Exelixis' stock experienced a decline in pre-market trading following the earnings announcement [2] Financial Performance - The growth in net revenues was primarily driven by higher product sales, with net product revenues reaching $546.6 million, a 6% increase year over year [4] - Cabometyx (cabozantinib) generated revenues of $544.7 million, slightly missing the Zacks Consensus Estimate of $554 million but marginally exceeding internal estimates [5][6] - Collaboration revenues totaled $52.1 million, reflecting a 1% year-over-year increase, mainly due to higher royalty revenues from cabozantinib sales outside the U.S. [8] Operating Expenses - Research and development expenses, including stock-based compensation, decreased by 14.4% year over year to $213.2 million, attributed to lower clinical trial costs [9] - Selling, general, and administrative expenses fell by 8% year over year to $123 million, primarily due to reductions in stock-based compensation and personnel costs [9] Share Repurchase Program - During the quarter, Exelixis repurchased $264.5 million in shares, completing a $500 million share repurchase program authorized in February 2025 [10] - Since the initiation of its first share repurchase program in March 2023, the company has repurchased a total of $2.16 billion in common stock [10] 2025 Results and 2026 Guidance - For 2025, Exelixis reported revenues of approximately $2.32 billion, a 7% increase from 2024, with adjusted EPS of $3.08, up from $2 in 2024 [11] - The company expects total revenues for 2026 to be between $2.525 billion and $2.625 billion, with net product revenues projected to be in the range of $2.325 billion to $2.425 billion [12] Pipeline and Regulatory Updates - Exelixis is developing zanzalintinib, a next-generation oral investigational tyrosine kinase inhibitor, with an NDA accepted by the FDA for previously treated metastatic colorectal cancer [14][15] - The company is also advancing several phase I assets and has two new investigational new drug filings planned for 2026 [21][22] Market Position and Future Outlook - Cabometyx remains a leading TKI monotherapy for renal cell carcinoma (RCC) and is gaining traction in the neuroendocrine tumor market [23] - The strong uptake of Cabometyx in the newly approved NET indication is expected to drive future sales growth [24] - The potential approval of zanzalintinib is viewed as a significant catalyst for Exelixis' oncology pipeline, with management expanding sales infrastructure to support growth [24][25]

Eli Lilly is paying $350 million upfront to collaborate with Chinese biotech Innovent in developing new treatments for cancer and immune disorders, a further vote of confidence for the innovation capabilities of the country’s drugmakers https://t.co/SViSaZ5qnn ...

Fears flight route changes could affect cancer patients https://t.co/9R1gAwMoHB ...

Core Insights - AngioDynamics (ANGO) is experiencing growth driven by its NanoKnife product and a focus on cancer treatment markets, supported by a strong second-quarter fiscal 2026 performance and ongoing studies [1][2] Financial Performance - AngioDynamics reported a revenue increase of 8.8% year over year to $79.4 million in fiscal Q2 2026, with the NanoKnife revenue rising 22.2% due to record prostate cancer procedure volumes [7][10] - The Auryon franchise generated $16.3 million in revenue, reflecting an 18.6% year-over-year growth, marking 18 consecutive quarters of double-digit growth [5][10] - The company has a market capitalization of $422.1 million and projects a 51.9% growth over the next year [2] Growth Drivers - The NanoKnife franchise is a key growth driver, with probe sales increasing 14.4% year over year, attributed to rising adoption in prostate cancer procedures [3][4] - Management noted steady adoption of NanoKnife, supported by procedural growth and increasing clinical utilization, particularly in the prostate cancer market [4] - The mechanical thrombectomy portfolio saw a revenue increase of 3.9% year over year to $11 million, with AlphaVac achieving over 40% growth [9] Market Position and Trends - AngioDynamics has gained 9.8% in share price over the last six months, outperforming the industry growth of 5.2% and the S&P 500's increase of 11.9% [1] - The company has been experiencing a positive estimate revision trend, with the Zacks Consensus Estimate for loss narrowing to 27 cents per share for fiscal 2026 [13] Challenges - Management acknowledged ongoing tariff-related costs of $4–$6 million for the fiscal year, which may pose a structural margin headwind [11][12]